南新制药拟公开挂牌转让部分应收账款

Core Viewpoint - Nanjing Pharmaceutical (688189) plans to transfer part of its subsidiary's accounts receivable through a public listing to optimize its asset structure and improve asset liquidity and safety [1] Group 1: Asset Transfer Details - The company intends to transfer accounts receivable with a total book balance of 48,978.4 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 45,979.45 million yuan, resulting in a net book value of 2,998.95 million yuan for the receivables being transferred [1] Group 2: Strategic Objectives - The asset transfer aims to reduce accounts receivable management costs and enhance the quality of asset operations [1] - This move is expected to support better operational development for the company and protect the legal rights of all shareholders [1]